NICHD Contraceptive Clinical Trials Network

The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Contraceptive Clinical Trials Network is a Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract focused on conducting clinical trials for contraceptive research and development. The contract supports the comprehensive evaluation of new and existing contraceptive methods, with a particular emphasis on male contraceptive options. The master IDIQ has a shared ceiling value of $35 million and was originally awarded on August 15, 2013, with a last ordering date of August 31, 2020.

Task orders under this IDIQ primarily involve clinical trials of male contraceptive products, with most contracts awarded to research institutions such as the University of Washington and the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. Typical task orders range from $413,627 to $11,791,957 in value, with performance periods generally spanning 3-7 years, concluding between 2017 and 2025. The contracts are consistently awarded on a cost no fee or firm fixed price basis, with no specific set-aside designations. Major research topics include evaluating chemical entities like nestronone gel, testosterone gel, and DMAU (a male contraceptive), with clinical trial sites primarily located in Washington state and California. The primary funding agency is the National Institute of Child Health and Human Development, which aims to expand contraceptive options through rigorous clinical research.